Sysmex and MolecularMD have signed a non-exclusive collaboration agreement focused on the development and commercialization of companion diagnostics for precision medicine.

Greiner Bio One International (Kremsmünster, Ober?sterreich, Austria) has launched the innovative VACUETTE SAFELINK tube holder with male luer lock that facilitates quick and easy blood collection.

The global point of care (POC) urinalysis market is projected to grow at a CAGR of more than 3% over the 2018-2022 period,

Danaher today initiated its earning outlook for 2019, saying EPS is anticipated to be in the range of $4.02 to $4.12.

Recently, Sansure Biotech and Thermo Fisher Scientific (hereinafter referred to as: Thermo Fisher) signed a strategic cooperation agreement.

GenMark Diagnostics announced recently it has received 510(k) clearance from the US Food and Drug Administration for a molecular diagnostic panel assay to detect fungal pathogens from blood cultures of patients with suspected blood stream infections.

Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan Food and Drug Administration（TFDA).

Foundation Medicine announced recently that its FoundationOne CDx genomic profiling assay has received regulatory approval from Japan's Ministry of Health, Labour and Welfare (MHLW).

Cepheid announced recently it has received CE-IVD clearance for a rapid molecular assay to measure viral load of hepatitis B in infected patients.

French diagnostics firm Novacyt announced recently that it has received CE marking for its Genesig BK virus (BKV) and Epstein-Barr virus (EBV) diagnostic kits, which are designed for use in post-transplantation and immunosuppressed patients.

Imagine being a pediatric kidney transplant patient and having to miss school or extracurricular activities because of clinic appointments and routine blood tests.

At the close of the 2014-2016 West Africa Ebola crisis, the Paul G. Allen Foundation identified diagnostic gaps as one of the major deficiencies that had contributed to the outbreak’s spread.

Brigham and Women’s Hospital investigators are working on a test that could either diagnose or predict Alzheimer’s disease before symptoms appear.

A long-awaited and massive study with major implications for the liquid biopsy market is slated to start next year.

Oxford HighQ has received ￡2.1 million in seed funding to commercialize components of a quantum computing technology developed at Oxford University that can be used to develop improved chemical and nanoparticle sensing technologies.